RECHERCHE ET ANALYSE: DOCUMENTS DE TRAVAIL
Patent-related actions taken in WTO members in response to the COVID-19 pandemic
COVID-19, caused by SARS-Cov-2, was declared to be a pandemic by the World Health Organization on 11 March 2020. Since then, the issue of the relationship between patent protection and the development of and access to medical treatments and technologies – a longstanding and enduringly important public policy issue – has become central to the debate on the linkages between IP, innovation, access, and public health between stakeholders with divergent interests.
This working paper provides an overview of the patent landscape of medical treatments and technologies related to COVID-19, and of the patent status of two investigational medical treatments: remdesivir and lopinavir/ritonavir. It then presents various patent-related actions taken by legislators, policymakers, industry sectors, and civil society organizations in WTO Members since the outbreak. Furthermore, it elaborates on patent-related policy options provided by the TRIPS Agreement, and WTO Members' national implementation and utilization of these options in their response to the COVID-19 pandemic.
No: ERSD-2020-12
Auteurs: Xiaoping Wu and Bassam Peter Khazin
Date de rédaction: octobre 2020
Mots clés:
COVID-19 pandemic, patent, open innovation, patentable subject matter, repurposed medicines, exceptions and limitations, licences, government use, transition periods, LDCs, WTO, TRIPS
Cotes JEL:
K11, K15, K30, O30, O31, O34, I18
haut de pageAvertissement
Ce document est un document de travail et concerne donc des recherches en cours. Les opinions qui y sont exprimées sont celles de ses auteurs. Elles ne sont pas censées représenter la position ou les opinions de l’OMC ou de ses Membres et sont sans préjudice des droits et obligations des Membres dans le cadre de l'Organisation. Les auteurs sont seuls responsables en cas d’erreur.
Télécharger le document en format pdf (38 pages, 797Ko; uniquement en anglais, ouvre une nouvelle fenêtre.)